Sangamo Biosciences Stock News

Banque Cantonale Vaudoise lessened its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 6.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 36,537 shares of the biopharmaceutical company’s stock after selling 2,713 shares during the period. Banque Cantonale Vaudoise’s holdings in Sangamo Therapeutics were worth $329,000 […]

Sangamo Therapeutics Inc. (NASDAQ:SGMO) has a beta value of 1.52 and has seen 1.0 million shares traded in the last trading session. The company, currently valued at $1.13B, closed the last trade at $8.28 per share which meant it gained $0.03 on the day or 0.36% during that session. The SGMO stock price is -134.66% Weak Fundamental Momentum Sinks Sangamo Therapeutics Inc. Read More »

The trading price of Sangamo Therapeutics Inc. (NASDAQ:SGMO) closed lower on Monday, December 13, closing at $7.29, -5.69% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years fol

(RTTNews) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years following Hemophilia A gene therapy. Giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, was

Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvov

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in patients with severe hemophilia A, are being presented today at the 63rd American Society for Hematology Annual Meeting and Exposition t

No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required bloo

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD). These data are being presented today at the 63rd American Society for Hematology Annual Meeting and Exposition taking place from December 11-14

Shares of Sangamo Therapeutics, Inc. reached a new 52-week low during mid-day trading on Friday following insider selling activity. The stock traded as low as $7.75 and last

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) reached a new 52-week low during mid-day trading on Friday following insider selling activity. The stock traded as low as $7.75 and last traded at $7.76, with a volume of 66523 shares. The stock had previously closed at $8.14. Specifically, major shareholder Biogen Inc. sold 52,178 shares of the [] The post Sangamo Therapeutics (NASDAQ:SGMO) Sets New 12-Month Low Following Insider Selling appeared first on ETF Daily News .

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) major shareholder Biogen Inc. sold 52,178 shares of Sangamo Therapeutics stock in a transaction that occurred on Tuesday, December 7th. The shares were sold at an average price of $8.52, for a total transaction of $444,556.56. The transaction was disclosed in a filing with the SEC, which is available at this []

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) major shareholder Biogen Inc. sold 28,884 shares of the companys stock in a transaction dated Friday, November 26th. The stock was sold at an average price of $8.60, for a total transaction of $248,402.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through []

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December